Structure Therapeutics Q2 net loss widens

Structure Therapeutics

06/08/2025 21:24

Overview

Structure Therapeutics Q2 net loss widens to $61.7 mln from $26.0 mln yr ago

Company holds $786.5 mln in cash, funding operations through 2027

ACCESS and ACCESS II studies on track for year-end 2025 data readouts

Outlook

Company anticipates cash position of $786.5 mln to fund operations through at least 2027

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to clinical trial costs and personnel expansion for GLP-1R franchise

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$61.66 mln
Q2 Income From Operations
-$70.45 mln
Q2 Operating Expenses
$70.45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Structure Therapeutics Inc is $75.00, about 77.8% above its August 5 closing price of $16.68

Press Release: ID:nGNX3TkbBL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)